Literature DB >> 25992374

Interaction non grata between CFTR's correctors and potentiators.

Wen-Ying Lin1, Ying-Chun Yu1.   

Abstract

Entities:  

Year:  2015        PMID： 25992374      PMCID： PMC4416958          DOI： 10.3978/j.issn.2305-5839.2015.01.27

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  24 in total

Review 1.  Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis.

Authors:  Margarida D Amaral; Karl Kunzelmann
Journal:  Trends Pharmacol Sci       Date:  2007-06-18       Impact factor: 14.819

2.  Altered chloride ion channel kinetics associated with the delta F508 cystic fibrosis mutation.

Authors:  W Dalemans; P Barbry; G Champigny; S Jallat; K Dott; D Dreyer; R G Crystal; A Pavirani; J P Lecocq; M Lazdunski
Journal:  Nature       Date:  1991 Dec 19-26       Impact factor: 49.962

3.  Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA.

Authors:  J R Riordan; J M Rommens; B Kerem; N Alon; R Rozmahel; Z Grzelczak; J Zielenski; S Lok; N Plavsic; J L Chou
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

4.  Vx-770 potentiates CFTR function by promoting decoupling between the gating cycle and ATP hydrolysis cycle.

Authors:  Kang-Yang Jih; Tzyh-Chang Hwang
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-25       Impact factor: 11.205

5.  Chloride impermeability in cystic fibrosis.

Authors:  P M Quinton
Journal:  Nature       Date:  1983-02-03       Impact factor: 49.962

6.  Some gating potentiators, including VX-770, diminish ΔF508-CFTR functional expression.

Authors:  Guido Veit; Radu G Avramescu; Doranda Perdomo; Puay-Wah Phuan; Miklos Bagdany; Pirjo M Apaja; Florence Borot; Daniel Szollosi; Yu-Sheng Wu; Walter E Finkbeiner; Tamas Hegedus; Alan S Verkman; Gergely L Lukacs
Journal:  Sci Transl Med       Date:  2014-07-23       Impact factor: 17.956

7.  Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner.

Authors:  Paul D W Eckford; Canhui Li; Mohabir Ramjeesingh; Christine E Bear
Journal:  J Biol Chem       Date:  2012-08-31       Impact factor: 5.157

8.  Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation.

Authors:  Frank J Accurso; Steven M Rowe; J P Clancy; Michael P Boyle; Jordan M Dunitz; Peter R Durie; Scott D Sagel; Douglas B Hornick; Michael W Konstan; Scott H Donaldson; Richard B Moss; Joseph M Pilewski; Ronald C Rubenstein; Ahmet Z Uluer; Moira L Aitken; Steven D Freedman; Lynn M Rose; Nicole Mayer-Hamblett; Qunming Dong; Jiuhong Zha; Anne J Stone; Eric R Olson; Claudia L Ordoñez; Preston W Campbell; Melissa A Ashlock; Bonnie W Ramsey
Journal:  N Engl J Med       Date:  2010-11-18       Impact factor: 176.079

9.  Modulation of CFTR gating by permeant ions.

Authors:  Han-I Yeh; Jiunn-Tyng Yeh; Tzyh-Chang Hwang
Journal:  J Gen Physiol       Date:  2014-12-15       Impact factor: 4.086

Review 10.  Quality control: quality control at the plasma membrane: one mechanism does not fit all.

Authors:  Markus Babst
Journal:  J Cell Biol       Date:  2014-04-14       Impact factor: 10.539
View more
  1 in total

1.  Efficacy of lumacaftor-ivacaftor for the treatment of cystic fibrosis patients homozygous for the F508del-CFTR mutation.

Authors:  Deborah M Cholon; Charles R Esther; Martina Gentzsch
Journal:  Expert Rev Precis Med Drug Dev       Date:  2016-04-22
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.